Usha Sharma – Mumbai
The Rs 15 crore Mumbai-based pharmaceutical company, Amra Remedies, established in 2010 has targeted a turnover of Rs 100 crore in financial year 2012-13. The company also plans to enter the diabetes therapeutic segment by 2014 and provide full line of treatment. It is currently in talks with a Japanese company manufacturing glucometers and a multinational company for obtaining co-marketing rights for the Indian market.
Talking exclusively with Express Pharma, Partha Banerjee, MD and CEO, Amra Remedies said, “We are in talks with the Japanese company for co-marketing of their glucometers in India. With the help of this agreement, we will be able provide to full line of treatment to patients. We are also in talks with another multinational pharma company as they hold the patent on our research molecule. We are in the final stages of discussion for co-marketing the diabetes product in India. Presently, it is available globally and we are targeting to launch the product by 2014 in India.”
Presently, Amra Remedies has over 45 products in its kitty for cardiovascular, dermatology, gynaecology, oncology, nutraceutical, anti-microbial, gastrointestinal and respiratory therapeutic segments. To continue its growth, the company plans to launch has five more new products in its existing therapeutic areas (two for dermatology and one each for anti-microbial, oncology and FMCG).
Banerjee highlighted, “We are mainly focusing on the anti-microbial therapeutic segment as we consider that this therapeutic segment has maj